Ischemic mitral regurgitation is the regurgitation seen with structurally normal valve leaflets that occurs in approximately 20% of patients after myocardial infarction and 56% of patients with congestive heart failure caused by ischemic or nonischemic cardiomyopathy. The initiating event is an ischemic insult that results in remodeling of the left ventricle toward a more spherical shape and new wall motion abnormalities. These changes lead to annular dilation and subvalvular distortion that prevent the mitral leaflets from coapting and closing completely during the contraction phase. Treatment options include coronary revascularization, ring annuloplasty, valve repair and replacement, or left ventricle reconstruction by way of localized reshaping or resection. Pharmacotherapy, aimed at raising left ventricular pressure without increasing tethering or left ventricular volume, is included in the treatment options for improving ischemic mitral regurgitation.